| Literature DB >> 24732791 |
Hanne D Hansen1, Enza Lacivita2, Pantaleo Di Pilato2, Matthias M Herth3, Szabolcs Lehel4, Anders Ettrup1, Valdemar L Andersen3, Agnete Dyssegaard1, Paola De Giorgio2, Roberto Perrone2, Francesco Berardi2, Nicola Antonio Colabufo2, Mauro Niso2, Gitte M Knudsen5, Marcello Leopoldo2.
Abstract
In the search for a novel serotonin 7 (5-HT7) receptor PET radioligand we synthesized and evaluated a new series of biphenylpiperazine derivatives in vitro. Among the studied compounds, (R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol ((R)-16), showed the best combination of affinity, selectivity, and lipophilicity, and was thus chosen for carbon-11 labelling and evaluation in pigs. After intravenous injection, [(11)C](R)-16 entered the pig brain and displayed reversible tracer kinetics. Pretreatment with the 5-HT7 receptor selective antagonist SB-269970 (1) resulted in limited decrease in the binding of [(11)C](R)-16, suggesting that this radioligand is not optimal for imaging the brain 5-HT7 receptor in vivo but it may serve as a lead compound for the design of novel 5-HT7 receptor PET radioligands.Entities:
Keywords: 5-HT(7) receptor; Arylpiperazine; PET; Radioligand; SB-269970
Mesh:
Substances:
Year: 2014 PMID: 24732791 DOI: 10.1016/j.ejmech.2014.03.066
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514